SAB Biotherapeutics to Showcase SAB-142 Data at 2026 Immunology of Diabetes Society Congress
Event summary
- SAB Biotherapeutics will present data on SAB-142 at the 2026 Immunology of Diabetes Society Congress in Brisbane, Australia, from April 20-24.
- The company will give an oral presentation and three poster presentations on SAB-142's clinical and mechanistic profile.
- SAB-142 is a disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 type 1 diabetes (T1D) patients.
- The SAFEGUARD study, a registrational Phase 2b clinical trial for SAB-142, is actively enrolling with topline data anticipated in the second half of 2027.
The big picture
SAB Biotherapeutics is positioning SAB-142 as a potentially best-in-class immunotherapy for type 1 diabetes, aiming to change the treatment paradigm by preserving insulin-producing beta cells. The upcoming data presentations at the Immunology of Diabetes Society Congress are critical for validating the therapeutic's mechanism of action and clinical profile. The company's proprietary technology, utilizing transchromosomic cattle to produce fully human antibodies, represents a novel approach in the biopharmaceutical industry.
What we're watching
- Clinical Data
- How the additional data on SAB-142's multi-specific binding profile and C-peptide data will impact its best-in-class potential.
- Regulatory Pathway
- Whether the SAFEGUARD study results will support a potential approval for SAB-142 in type 1 diabetes.
- Market Positioning
- The pace at which SAB Biotherapeutics can differentiate SAB-142 from existing treatments like rabbit ATG (rATG).
Related topics